Latest Immunosuppressive drug Stories
DEERFIELD, Ill., May 28 /PRNewswire/ -- The Food and Drug Administration (FDA) has granted Astellas Pharma US, Inc. approval for the use of Prograf(R) (tacrolimus) in conjunction with mycophenolate mofetil (MMF) for the prevention of organ rejection in kidney transplant recipients.
Trial to Evaluate Safety of CCL2-LPM for Inflammatory Kidney Disease SAN FRANCISCO, April 14 /PRNewswire/ -- Osprey Pharmaceuticals U.S.A., Inc.
An Australian-led scientific team says it's developed a therapy that might eventually negate the need for immunosuppressive drugs after organ transplants. Professor Jonathan Sprent and Dr. Kylie Webster from Sydney's Garvan Institute of Medical Research, in collaboration with U.S.
Australian scientists have made a discovery that may one day remove the need for a lifetime of toxic immunosuppressive drugs after organ transplants.
Devices helps prevent complete vision loss and eliminate dependence on systemic immunosuppression for rare, but potentially devastating, eye condition.
LOUISVILLE, Ky., Feb. 17 /PRNewswire-USNewswire/ -- The United States' fifth hand transplant recipient, Jan "Erik" Hondusky, is heading back home to Massena, New York this week after a three-month stay in Louisville under the care of Kleinert Kutz and University of Louisville surgeons.
To prevent the rejection of newly transplanted organs and cells, patients must take medicines that weaken their entire immune systems. Such potentially life-saving treatments can, paradoxically, leave those receiving them susceptible to life-threatening infections.
Scientists at the University of Michigan Department of Dermatology, the U-M School of Public Health and their collaborators have found DNA "hotspots" that may reveal how genetic differences among individuals result in psoriasis, an autoimmune disease of the skin.
Scientists at UCSF have discovered an abnormality in a patientâ€™s immune system that may lead to safer therapies for autoimmune diseases such as rheumatoid arthritis and colitis, as well as potential new ways to treat transplant rejection.
First and Only Biologic Approved with Infrequent, Every Twelve-Week Maintenance Dosing BEERSE, Belgium, Jan. 22 /PRNewswire/ -- Janssen-Cilag announced today that STELARA(TM) (ustekinumab), the first in a new class of biologics, has been approved by the European Commission for use across Europe.
- A person or thing gazed at with wonder or curiosity, especially of a scornful kind.